NEW YORK--(BUSINESS WIRE)--LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of InspireMD, Inc. (OTCBB: NSPR), a device company focused on the development and commercialization of novel metal stent systems. InspireMD’s lead product, the MGuard and MGuard Prime stent system, which are already CE Mark approved and sold in multiple geographies including Europe, Canada, Southeast Asia, India and Latin America, is designed to reduce embolization during coronary interventions. The MGuard stent system has been evaluated in over 500 patients in clinical studies with over 15,000 stents installed commercially.
“The MGuard system, which includes a novel mesh sleeve covering the accompanying stent, provides a highly deliverable solution designed to block embolic debris present in patients with high thrombotic burden undergoing PCI, namely the high-risk acute myocardial infarction (AMI) patients that are at risk for distal embolism during the stenting procedure,” stated Andrew I. McDonald, Ph.D., Managing Director at LifeSci Advisors. “A significant portion of the AMI segment, which accounts for approximately one-third of the $5.5 billion global stent market, is addressed by the MGuard stent system.”
In a 46-page Initiation Report by LifeSci Advisors, the MGuard preclinical, clinical, and commercial aspects are reviewed, as is a detailed analysis of the overall stent market. MGuard is currently being evaluated against BMS/DES (physician’s choice) in the MASTER trial, a randomized (1:1) trial (n=432), with data expected mid-2012. The FDA approval trial is set to initiate recruitment in 1Q 2012.
Dr. McDonald’s full Initiation Report is available to download at no cost at the LifeSci Advisors website, http://lifesciadvisors.com/clients/. In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on the Company as developments occur.
The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics.
About LifeSci Advisors:
LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company’s website, www.lifesciadvisors.com.
Important Disclosures:
The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website, http://lifesciadvisors.com/disclaimer/, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer.
Forward-looking statements:
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.